CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?
CD24
CD44
bladder cancer organoids
bladder cancer stem-cell marker
immune checkpoint antigens
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 May 2022
13 May 2022
Historique:
received:
04
04
2022
revised:
03
05
2022
accepted:
09
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Bladder cancer is the most cost-intensive cancer due to high recurrence rates and long follow-up times. Bladder cancer organoids were considered interesting tools for investigating better methods for the detection and treatment of this cancer. Organoids were generated from urothelial carcinoma tissue samples, then expanded and characterized; the expression of immune modulatory antigens and tumor stem cells markers CD24 and CD44 was explored in early (P ≤ 3) and later (P ≥ 5) passages (P) by immunofluorescence and by quantitative PCR of cDNA. The expression of these factors was investigated in the corresponding cancer tissue samples by immunohistochemistry. The expression of the PD-L1 was detected on some but not all organoids. CD276 and CD47 were observed on organoids in all passages investigated. Organoids growing beyond passage 8 expressed both CD24 and CD44 at elevated levels in early and late cultures. Organoids proliferating to the eighth passage initially expressed both CD24 and CD44, but lost CD24 expression over time, while CD44 remained. Organoids growing only up to the 6th passage failed to express CD24 but expressed CD44. The data indicate that the expression of CD24 in urothelial cancer cell organoids may serve as an indicator for the prolonged proliferation potential of the cells.
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer is the most cost-intensive cancer due to high recurrence rates and long follow-up times. Bladder cancer organoids were considered interesting tools for investigating better methods for the detection and treatment of this cancer.
METHODS
METHODS
Organoids were generated from urothelial carcinoma tissue samples, then expanded and characterized; the expression of immune modulatory antigens and tumor stem cells markers CD24 and CD44 was explored in early (P ≤ 3) and later (P ≥ 5) passages (P) by immunofluorescence and by quantitative PCR of cDNA. The expression of these factors was investigated in the corresponding cancer tissue samples by immunohistochemistry.
RESULTS
RESULTS
The expression of the PD-L1 was detected on some but not all organoids. CD276 and CD47 were observed on organoids in all passages investigated. Organoids growing beyond passage 8 expressed both CD24 and CD44 at elevated levels in early and late cultures. Organoids proliferating to the eighth passage initially expressed both CD24 and CD44, but lost CD24 expression over time, while CD44 remained. Organoids growing only up to the 6th passage failed to express CD24 but expressed CD44.
CONCLUSIONS
CONCLUSIONS
The data indicate that the expression of CD24 in urothelial cancer cell organoids may serve as an indicator for the prolonged proliferation potential of the cells.
Identifiants
pubmed: 35628262
pii: ijms23105453
doi: 10.3390/ijms23105453
pmc: PMC9141653
pii:
doi:
Substances chimiques
B7 Antigens
0
Biomarkers, Tumor
0
CD24 Antigen
0
CD24 protein, human
0
CD276 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 663952
Références
Cancer Res. 1994 May 1;54(9):2462-7
pubmed: 8162595
Nat Genet. 2010 Nov;42(11):978-84
pubmed: 20972438
World J Gastroenterol. 2013 May 7;19(17):2603-11
pubmed: 23674867
Oncotarget. 2018 Oct 5;9(78):34719-34734
pubmed: 30410672
Int J Mol Sci. 2022 Jun 04;23(11):
pubmed: 35682984
Cancers (Basel). 2022 Apr 20;14(9):
pubmed: 35565191
World J Urol. 2020 Aug;38(8):1895-1904
pubmed: 31676912
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3021-3028
pubmed: 31334674
J Immunol. 1981 Jan;126(1):83-8
pubmed: 6969748
Oncoimmunology. 2018 Feb 15;7(4):e1345415
pubmed: 29632713
Eur J Histochem. 2015 Nov 03;59(4):2532
pubmed: 26708177
EMBO Mol Med. 2017 Jul;9(7):869-879
pubmed: 28468934
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4567-4574
pubmed: 30787188
Cell. 2018 Apr 5;173(2):515-528.e17
pubmed: 29625057
Nat Med. 2006 Oct;12(10):1175-80
pubmed: 16998483
Cell Rep. 2022 Feb 15;38(7):110384
pubmed: 35172142
Indian J Clin Biochem. 2017 Jul;32(3):292-300
pubmed: 28811688
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
J Cell Physiol. 2019 Jun;234(6):8381-8395
pubmed: 30417375
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Br J Cancer. 2018 Oct;119(8):961-970
pubmed: 30327565
Cell Mol Life Sci. 2012 Nov;69(22):3863-79
pubmed: 22760497
Nat Rev Urol. 2019 Oct;16(10):613-630
pubmed: 31501534
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):75-87
pubmed: 11033298
J Mol Histol. 2004 Mar;35(3):255-62
pubmed: 15339045
Eur Urol. 2009 Sep;56(3):430-42
pubmed: 19576682
Bioengineered. 2020 Dec;11(1):572-581
pubmed: 32434417
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Bladder Cancer. 2016 Oct 27;2(4):449-463
pubmed: 28035326
Cancer Sci. 2016 Jul;107(7):875-81
pubmed: 27116333
Curr Opin Urol. 2010 Sep;20(5):393-7
pubmed: 20657288
Int J Clin Exp Pathol. 2014 May 15;7(6):2934-41
pubmed: 25031712
Cancer Sci. 2010 Feb;101(2):416-24
pubmed: 19961489
Cancer Manag Res. 2019 May 23;11:4677-4690
pubmed: 31213893
Biomolecules. 2019 Nov 26;9(12):
pubmed: 31779287
Cancer Res. 2000 Dec 1;60(23):6714-22
pubmed: 11118057
J Immunol. 2014 Mar 1;192(5):2449-59
pubmed: 24501201
Urol Oncol. 2014 Jul;32(5):678-86
pubmed: 24631171
Transl Oncol. 2020 Feb;13(2):193-200
pubmed: 31869744
Breast Cancer Res. 2009;11(6):R82
pubmed: 19906290
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Cancer Res. 2005 Dec 1;65(23):10783-93
pubmed: 16322224
J Signal Transduct. 2011;2011:738137
pubmed: 21785723
Tumour Biol. 2016 Oct;37(10):14069-14081
pubmed: 27507615
Cancer Res. 2006 Feb 15;66(4):1917-22
pubmed: 16488989
J Cell Physiol. 2019 Apr;234(4):3197-3206
pubmed: 30471107
J Neuropathol Exp Neurol. 1999 Aug;58(8):795-802
pubmed: 10446804
Sci Rep. 2020 Jun 10;10(1):9393
pubmed: 32523078
Trends Immunol. 2020 Aug;41(8):652-664
pubmed: 32654925
Cancer Res. 2021 Jun 1;81(11):2833-2846
pubmed: 33687952
Int Immunopharmacol. 2006 Apr;6(4):672-7
pubmed: 16504931
Cells. 2020 Jan 17;9(1):
pubmed: 31963556
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Cancer Res. 2011 Jun 1;71(11):3802-11
pubmed: 21482678
Cancer Sci. 2019 Sep;110(9):2806-2821
pubmed: 31254429
Cancer Biol Ther. 2021 Jun 3;22(5-6):357-371
pubmed: 34034619
Cancer Lett. 2012 Sep 1;322(1):70-7
pubmed: 22343321
Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3588-96
pubmed: 23012401
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Sep;165(3):316-321
pubmed: 32424373
Cancer Res. 1995 Oct 15;55(20):4717-21
pubmed: 7553654
Urology. 2004 Apr;63(4):688-93
pubmed: 15072882
Biochem Biophys Res Commun. 2008 Jan 4;365(1):35-41
pubmed: 17980703
Am J Cancer Res. 2019 Dec 01;9(12):2774-2788
pubmed: 31911861